SCHEMBL25848826

SCHEMBL25848826

CS(=O)(=O)c1ccc(C(=O)NCc2ccc(C3CC3)cc2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.47
HDAC3 O15379 3/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC4 P56524 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HRH1 P35367 1/20 0.40
CCR3 P51677 1/20 0.40
LMNA P02545 2/20 0.40
PDE2A O00408 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PDE10A Q9Y233 1/20 0.39
KLKB1 P03952 1/20 0.39
ALDH2 P05091 1/20 0.39
ALDH1A1 P00352 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
DRD3 P35462 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25848805 0.88 USP5 (0.46) USP5HDAC3HDAC1HDAC4HDAC6
SCHEMBL25848839 0.83 ALDH1A1 (0.49) HDAC3HDAC1HDAC4HDAC6LMNA
SCHEMBL25848823 0.80 EPHX2 (0.61) HDAC3HDAC6LMNAEPHX2NR1H4
SCHEMBL25848811 0.80 SMN1; SMN2 (0.51) HDAC3HDAC1HDAC4HDAC6HRH1
SCHEMBL25848829 0.80 HDAC3 (0.40) HDAC3HDAC1HDAC4HDAC6KDM4E
SCHEMBL24196149 0.79 HDAC3 (0.44) HDAC3HDAC1HDAC4HDAC6HRH1
SCHEMBL25848940 0.79 LSS (0.50) HDAC3HDAC1HDAC4HDAC6EPHX2
SCHEMBL24195869 0.79 KDM4E (0.46) USP5HDAC3HDAC1HDAC4HDAC6
SCHEMBL25307432 0.79 HDAC3 (0.47) HDAC3HDAC1HDAC4HDAC6HRH1
SCHEMBL25849286 0.78 F10 (0.40) USP5HRH1CCR3LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
EP-4175624-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2023-05-10 EP disclosed
CN-116075297-A KCNT1 inhibitors and methods of use 普拉西斯精密医药公司 2023-05-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 USP5 4082/4885HDAC3 1223/4885HDAC1 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.